Latest Peptidase Stories

AACHEN, Germany and CHICAGO, April 19, 2013 /PRNewswire/ -- Grunenthal Group is pleased to announce their active participation in the 2013 BIO International Convention, the world's largest event for the biotechnology industry. The family owned, research driven pharmaceutical company headquartered in Aachen, Germany, will be sharing with the Biotech community exciting developments in the NCE pipeline for pain and inflammation as well as the tamper-resistant formulation technology...

MENLO PARK, California and BALLERUP, Denmark, March 18, 2013 /PRNewswire/ -- Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S inhibitor. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The first Phase 1 trial of VBY-891 is a double-blind,...

Cancer cells are resourceful survivors with plenty of tricks for staying alive. Researchers have uncovered one of these stratagems, showing how cells lacking the tumor suppressor BRCA1 can resume one form of DNA repair, sparing themselves from stagnation or death. The study appears in the January 21st issue of The Journal of Cell Biology. The BRCA1 protein helps to mend double-strand DNA breaks by promoting homologous recombination. Without it, cells can amass broken, jumbled, and fused...

Johns Hopkins team first identified biochemical clue to therapy in brain scans of people with MS Johns Hopkins researchers report the successful use of a form of MRI to identify what appears to be a key biochemical marker for cognitive impairment in the brains of people with multiple sclerosis (MS). In follow-up experiments on mice with a rodent form of MS, researchers were able to use an experimental compound to manipulate that same marker and dramatically improve learning and memory....